Radioactive Patients in the Emergency Dept
A patient who recently had a PET or nuclear medicine scan, received radionuclide therapy, or carries implanted radioactive seeds can arrive in the emergency department as a low-level radiation source—and the external dose to staff is almost always small and never a reason to delay emergency care. The right response is to understand the source, estimate the dose rate with a simple inverse-square calculation, confirm it with a survey meter, and manage it with time, distance, standard contamination precautions, and a call to the radiation safety officer (RSO).13
Emergency and acute-care staff are trained to worry about a radioactive patient, and that instinct is healthy—but it is frequently out of proportion to the actual hazard. The physics is well understood and the numbers are reassuring for diagnostic patients and manageable for therapy patients. This article gives emergency physicians, nurses, surgeons, and RSOs a practical, quantitative framework: which patients matter, how to estimate staff dose, what precautions actually help, and how the regulations frame the problem. DRPS supports facilities with this planning through its radiation safety officer and radiation safety training services.
Introduction
The guiding principle is simple: clinical care comes first, and radiation safety is layered on top without impeding it. No emergency intervention—resuscitation, intubation, surgery, imaging—should ever be withheld or delayed because a patient contains medical radioactivity. The doses involved in caring for these patients are, in the overwhelming majority of cases, a small fraction of occupational limits.278
Three categories of patient can present this way:
- Diagnostic nuclear medicine and PET patients, who were recently injected with short-lived tracers such as Tc-99m agents or F-18 FDG. These patients contain modest activity that decays quickly; the external hazard is low and transient.
- Radionuclide therapy patients, who received larger activities of longer-lived radionuclides such as I-131, Lu-177, or Ra-223. These patients can have meaningful external dose rates (especially I-131) and can excrete activity in body fluids, so both external dose and contamination control matter until they meet release criteria.
- Permanent-implant patients, who carry low-energy seeds such as I-125 or Pd-103 from prostate brachytherapy. These emit very low-energy photons that are mostly absorbed in tissue, so routine care is safe, with special attention only in surgery near the implant or after death.
The task for the care team is to recognize which category applies and respond proportionately.45 This builds on our guides to patient release after radiopharmaceutical therapy and the time, distance, and shielding fundamentals of external-dose control.
Topic Explanation
The patient as a radiation source
A patient who has been administered a radiopharmaceutical is, from a radiation-protection standpoint, a distributed source of photons. For external-dose estimation at typical bedside distances, treating the patient as a point source is a reasonable and slightly conservative approximation. What matters is:
- The radionuclide's photon emissions. High-yield, higher-energy photon emitters (F-18 and other 511 keV positron emitters, I-131 at 364 keV) produce higher external dose rates per unit activity than low-energy emitters (Tc-99m at 140 keV, and especially I-125 and Pd-103 at tens of keV).69
- The retained activity. This is the administered activity reduced by physical decay and by biological clearance (urination, in particular, removes a large fraction of many tracers).
- Distance. External dose rate follows the inverse-square law, so distance is the most powerful and cheapest control.
- Time. Cumulative dose is the dose rate integrated over contact time; short, efficient encounters keep it low.
For contamination (a separate pathway), what matters is whether the radionuclide is excreted in body fluids while the patient is in the department, which is relevant mainly for therapy patients.4
Why diagnostic patients are a minor concern
Diagnostic activities are small and the radionuclides are short-lived. A Tc-99m study (140 keV, 6-hour half-life) or an F-18 FDG study (511 keV, roughly 110-minute half-life) leaves the patient with activity that is both limited and rapidly declining—F-18 loses half its activity every two hours, and much of the tracer is cleared by voiding. Measured operating-room data for F-18 FDG patients show effective doses to the closest staff on the order of tens of microsieverts for an entire procedure, which is why intraoperative use of FDG has been judged acceptable from a staff-safety standpoint.7 Breast sentinel-node studies with Tc-99m produce such low exposures that a surgeon could perform thousands of hours of procedures before approaching occupational limits.8
Why therapy patients deserve real attention
Therapy changes the arithmetic. An I-131 thyroid cancer patient may be treated with several gigabecquerels, and I-131's 364 keV photons are penetrating. Until the patient is released under the dose criteria, whole-body dose rates can be on the order of a few tenths of a millisievert per hour at 1 meter. Lu-177 therapies involve lower photon yield but still warrant contamination control, and Ra-223 is dominated by alpha emission—essentially no external hazard, but a contamination-control concern for body fluids.46
Key Technical Principles
Estimating the dose rate
The bedside estimate uses the specific gamma-ray (air-kerma) rate constant and the inverse-square law:
where
and in practice is reduced further by biological clearance. The inverse-square term is the lever worth remembering at the bedside: doubling the distance from 0.5 m to 1 m cuts the dose rate to one quarter.
Representative values
The table gives representative specific gamma-ray constants and typical scenarios. The constants are illustrative starting points compiled from published radionuclide data and should be verified against the specific dataset used for any formal calculation.69
| Radionuclide (use) | Key photon(s) | Representative Γ (µGy·m²·MBq⁻¹·h⁻¹) | Typical activity | Dominant concern for ED staff |
|---|---|---|---|---|
| Tc-99m (diagnostic) | 140 keV | ~0.019 | ~740 MBq | Low external; standard precautions |
| F-18 FDG (PET) | 511 keV | ~0.143 | ~370 MBq | Low–moderate external, short-lived |
| Ga-68 (PET) | 511 keV | ~0.134 | ~150 MBq | Low external, very short-lived |
| I-131 (thyroid cancer therapy) | 364 keV | ~0.052–0.066 | up to several GBq | External dose and contamination |
| Lu-177 (DOTATATE/PSMA therapy) | 113, 208 keV | ~0.007–0.008 | ~7.4 GBq | Mainly contamination; modest external |
| Ra-223 (bone therapy) | low yield | very low | ~kBq/kg scale | Contamination (alpha); minimal external |
| I-125 / Pd-103 (permanent seeds) | 27–35 keV / 21 keV | very low external | implanted | Minimal; seed recovery in surgery |
A worked example: the FDG patient in the ED
Suppose a patient was injected with 370 MBq of F-18 FDG for a PET scan and arrives in the ED about one hour later. F-18 has a half-life of roughly 110 minutes, so after 60 minutes the physical decay factor is:
(before accounting for any voiding, which would lower it further). The dose rate at 1 meter is then:
So about 0.036 mGy/h (roughly 36 µSv/h) at 1 meter. A nurse spending 30 minutes at 1 meter would receive on the order of 18 µSv, and the rate keeps falling as the F-18 decays. Compare that with the 50 mSv annual occupational limit: it would take hundreds of such encounters to approach the limit, which is why routine care of diagnostic patients is not a dose concern.27
The contrast with I-131 therapy
Run the same calculation for an I-131 thyroid-cancer patient shortly after a 5.5 GBq (about 150 mCi) treatment:
This is why I-131 patients are hospitalized or released only when they meet the dose criteria, and why an I-131 patient presenting acutely is the scenario that genuinely calls for time-distance management, rotation of staff for prolonged contact, and RSO involvement. Under NRC Regulatory Guide 8.39, the default release benchmark for I-131 corresponds to a measured dose rate of about 0.07 mSv/h at 1 meter (using a 0.25 occupancy factor at 1 meter), which ties the bedside survey reading directly to the regulatory framework.3
Clinical Impact
Care is never delayed
The single most important clinical message is that the external hazard from a radioactive patient is not a reason to withhold or delay emergency care. The doses to staff are low for diagnostic patients and manageable for therapy patients, and the consequences of delaying resuscitation, surgery, or stabilization are vastly larger than any radiation risk.2 Radiation safety operates in parallel with care, not ahead of it.
Surgery and procedures
When a recently injected patient needs an urgent procedure, the close, sustained contact raises the question of hands and torso dose to the surgical team. The data are reassuring: measured effective doses to the primary surgeon from FDG patients are on the order of tens of microsieverts per case, and sentinel-node Tc-99m procedures produce exposures so low that thousands of hours would be needed to reach limits.78 Practical steps—efficient technique, awareness of the injection site, dose monitoring for staff who do many such cases, and handling of specimens and sharps as potentially contaminated until surveyed—keep doses ALARA without changing surgical care.
Contamination awareness
For therapy patients, body fluids can carry activity. Standard precautions (gloves, gowns, careful handling) that are already universal in emergency care address most of the contamination pathway; the additions are to contain soiled linens and absorbent materials for the RSO to survey and manage, and to survey hands and surfaces after close care of an I-131 or Lu-177 patient. Alpha emitters such as Ra-223 are essentially an external non-issue but a contamination item.4
Death in the department
If a radioactive patient dies, the RSO is notified. For diagnostic activities, decay resolves the issue quickly. For therapy patients, retained activity can affect autopsy, embalming, burial, and cremation, and is addressed by established guidance (NCRP Report No. 155 and ICRP Publication 94) and by recent NRC advisory recommendations on patient death shortly after radioactive-material administration. The RSO determines any restrictions based on radionuclide and retained activity.4511
Practical Optimization Tips
A workable emergency-department protocol follows a short sequence.
1. Treat the patient
Stabilize and treat first. Radiation precautions are implemented around care, never instead of it.2
2. Identify the source
Ask about recent nuclear medicine or PET scans and any radionuclide therapy; look for a patient release card, discharge instructions, or wristband. Establish the radionuclide, the approximate activity, and the time since administration.3
3. Notify nuclear medicine or the RSO
For anything beyond a routine diagnostic patient—especially a known therapy patient—contact nuclear medicine or the RSO early for a dose-rate estimate and precaution guidance.
4. Survey if a meter is available
A calibrated survey meter reading at 1 meter confirms the estimate and lets you track decline. For I-131 patients, relate the reading to the release benchmark.3
5. Apply time and distance
Keep non-essential staff back, work efficiently, and step away between tasks. Inverse square means distance is the most effective control. Rotate staff for any prolonged close-contact procedure.
6. Use standard precautions for fluids
Gloves and standard precautions handle most contamination; contain soiled materials for RSO survey, and survey hands and surfaces after close care of a therapy patient.4
7. Document
Record the radionuclide, estimated activity, dose-rate readings, precautions taken, and any staff monitoring. Documentation supports both patient care and the radiation-protection program.
Common pitfalls to avoid
- Delaying care over radiation fear. The hazard is low; the care is urgent.2
- Treating all radioactive patients alike. A diagnostic Tc-99m patient and a fresh I-131 therapy patient are very different problems.6
- Forgetting contamination for therapy patients while over-worrying external dose for diagnostic ones.4
- Assuming permanent seeds are hazardous. Low-energy seeds pose minimal external risk; the issues are seed recovery in surgery and post-mortem handling.5
- Not calling the RSO when a therapy patient or a death is involved.
Regulatory Considerations
The framework comes from the NRC (or Agreement State) medical-use and radiation-protection rules, supported by national and international guidance.
- 10 CFR 35.75 governs the release of individuals containing unsealed byproduct material or implants, allowing release when the total effective dose equivalent to any other individual is not likely to exceed 5 mSv (0.5 rem). This is the rule under which a therapy patient was released, and it frames how to think about dose to others.1
- 10 CFR Part 20 sets the dose limits that contextualize staff exposure: 50 mSv per year total effective dose equivalent for occupational workers, 1 mSv per year for members of the public, and a 5 mSv embryo/fetus limit over the declared pregnancy. Emergency staff caring for a radioactive patient act as occupational workers in that role, and realistic doses are far below these limits.2
- NRC Regulatory Guide 8.39 provides the release methodology, default occupancy factors, and radionuclide-specific dose-rate benchmarks that tie a bedside survey to the regulatory criteria.3
- NCRP Report No. 155 (management of radionuclide therapy patients) and ICRP Publication 94 (release of patients after therapy with unsealed radionuclides) provide the clinical radiation-safety guidance, including precautions for acute care and death.45
- 10 CFR Part 35 governs medical use generally, including the authorized user's and RSO's responsibilities.10
In the United States, radioactive material is regulated by the NRC or an Agreement State. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States administering their own programs, while Washington, DC and Delaware are regulated directly by the NRC. Facilities should build their emergency-department radioactive-patient procedures into the radiation protection program and coordinate them with RSO consulting and staff radiation safety training.
Frequently Asked Questions (FAQs)
Is it dangerous for emergency staff to treat a patient who had a nuclear scan?
In almost all cases, no. A patient who had a diagnostic nuclear medicine or PET scan contains a small, decaying amount of short-lived activity, and the external dose rate to staff is low—typically a fraction of a millisievert per hour at 1 meter immediately after injection and falling quickly. Emergency and life-saving care must never be delayed over radiation concerns; the measured and modeled doses to staff from caring for these patients are well within occupational limits.
How do you estimate the dose rate from a radioactive patient?
Model the patient as a point source and use the inverse-square relationship: dose rate equals the radionuclide's specific gamma-ray constant times the retained activity divided by the distance squared. Correct the administered activity for physical decay and, where relevant, biological clearance (for example, voiding). Doubling the distance cuts the dose rate to one quarter, so stepping back is the fastest control. A calibrated survey meter confirms the estimate at the bedside.
Which patients actually require meaningful precautions?
Therapy patients are the ones that matter most—especially those recently treated with I-131 for thyroid cancer, where whole-body dose rates can be on the order of a few tenths of a millisievert per hour at 1 meter until the patient meets release criteria. Patients who had diagnostic Tc-99m or F-18 FDG studies, or who carry low-energy permanent seed implants such as I-125 or Pd-103, pose very little external hazard, though contamination awareness still applies to therapy patients' body fluids.
What about contamination from body fluids?
For diagnostic studies the main excretion is in urine, and standard (universal) precautions already handle it. For therapy radionuclides excreted in urine, saliva, sweat, or vomit—such as I-131 and Lu-177—gloves, careful handling of body fluids, containment of soiled materials, and a post-care survey of hands and surfaces are the key steps. Alpha emitters such as Ra-223 are primarily a contamination-control concern, not an external-dose concern.
Do permanent implant seeds make a patient hazardous in the ED?
Generally not. Permanent prostate implants using I-125 or Pd-103 emit very low-energy photons that are largely absorbed within the patient's own tissue, so external dose rates are very low and routine care is safe. The main special considerations arise in surgery near the implant (a dislodged seed should be recovered and handled per protocol) and at autopsy or cremation, where the RSO and established guidance should be consulted.
What should the emergency department do when a radioactive patient arrives?
Deliver clinical care first. Then identify the exposure (ask about recent scans or therapy, look for a patient release card or wristband), notify nuclear medicine or the radiation safety officer, survey the patient with a calibrated meter if available, apply time and distance, use gloves and standard precautions for body fluids, and document the encounter. Rotate staff if an extended close-contact procedure is needed, and let the RSO advise on any waste or contaminated materials.
What happens if a radioactive patient dies in the emergency department?
Notify the radiation safety officer immediately. For most diagnostic activities the short half-life makes the issue moot within hours. For therapy patients, retained activity can affect autopsy, embalming, burial, and cremation decisions, and national guidance (NCRP Report No. 155 and ICRP Publication 94) plus recent NRC advisory recommendations address precautions and documentation. The RSO determines what, if any, restrictions apply based on the radionuclide and retained activity.
Key Takeaways
- Care first, always. The external hazard from a radioactive patient is low and is never a reason to delay emergency treatment.2
- Estimate with inverse square. Dose rate equals the gamma constant times retained activity over distance squared; doubling distance quarters the dose.6
- Diagnostic patients are a minor concern. Short-lived, low-activity tracers give staff doses measured in microsieverts.78
- Therapy patients—especially fresh I-131—need real management. A few tenths of a millisievert per hour at 1 meter, plus contamination control for body fluids.34
- Permanent seeds are low-risk except for seed recovery in surgery and post-mortem handling.5
- Call the RSO, survey, document. Identify the radionuclide, apply time and distance, and tie survey readings to the regulatory benchmarks.13
Conclusion
The radioactive patient in the emergency department is a problem that feels bigger than it is. For the great majority—diagnostic nuclear medicine and PET patients—the external dose to staff is a few microsieverts and the correct action is simply to provide care and use standard precautions. For the minority who matter—recent I-131 therapy patients above all—the hazard is real but modest and fully manageable with time, distance, contamination control, and RSO involvement. The combination that works is a care-first culture, a one-line dose-rate estimate anyone on the team can do, a survey meter to confirm it, and a protocol that routes the harder cases to the radiation safety officer. Facilities that put that framework in place protect their staff without ever letting radiation fear compromise patient care.
How DRPS Can Help
Diagnostic Radiation Physics Services helps hospitals and imaging centers build practical radioactive-patient procedures for the emergency department, operating room, and inpatient units—dose-rate reference tables, survey protocols, contamination-control steps, death-and-autopsy guidance, and staff training—integrated into the facility's radiation protection program. Our support includes radiation safety officer services, radiation safety training, and medical physicist consulting.
DRPS serves facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.
Good procedures let the care team do what it does best, with radiation safety running quietly in the background.
Related Resources
- Patient release after radiopharmaceutical therapy
- Inpatient I-131 therapy radiation safety
- Holding patients for imaging: caregiver dose
- The contaminated patient: emergency response
- Postmortem radiation safety after radiopharmaceutical therapy
- Time, distance, and shielding for external dose
- Radiation Safety Officer consulting
- Radiation safety training
References
- U.S. Nuclear Regulatory Commission. 10 CFR 35.75: Release of individuals containing unsealed byproduct material or implants containing byproduct material. ecfr.gov
- U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
- U.S. Nuclear Regulatory Commission. Regulatory Guide 8.39: Release of Patients Administered Radioactive Material. nrc.gov
- National Council on Radiation Protection and Measurements. NCRP Report No. 155: Management of Radionuclide Therapy Patients. 2006. ncrponline.org
- International Commission on Radiological Protection. ICRP Publication 94: Release of Patients After Therapy with Unsealed Radionuclides. Ann ICRP. 2004;34(2). icrp.org
- Smith DS, Stabin MG. Exposure rate constants and lead shielding values for over 1,100 radionuclides. Health Phys. 2012;102(3):271-291. doi:10.1097/HP.0b013e318235153a. doi.org
- Heckathorne E, Dimock C, Dahlbom M. Radiation dose to surgical staff from positron-emitter-based localization and radiosurgery of tumors. Health Phys. 2008;95(2):220-226. doi:10.1097/01.HP.0000310962.96089.44. doi.org
- Stratmann SL, McCarty TM, Kuhn JA. Radiation safety with breast sentinel node biopsy. Am J Surg. 1999;178(6):454-457. doi:10.1016/s0002-9610(99)00230-5. doi.org
- International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Ann ICRP. 2008;38(3). icrp.org
- U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
- U.S. Nuclear Regulatory Commission, Advisory Committee on the Medical Uses of Isotopes. Recommendations on Patient Death Shortly After Radioactive Material Administration. 2025. nrc.gov
Related Articles
-
Patient Radiation Alarms After Nuclear Medicine
Why nuclear medicine patients trigger security radiation alarms for days to months, how long by isotope, and what NRC Reg Guide 8.39 expects licensees to do.
-
Type A and Type B Packages: A1/A2 Limits
A1 and A2 activity limits decide whether radioactive material ships in a Type A or Type B package. This guide covers the values, the sum-of-fractions rule, and the Q-system.
-
Radionuclide Decorporation and Chelation
Radionuclide decorporation and chelation: DTPA for plutonium/americium, Prussian blue for cesium, blocking and dilution agents, timing, committed dose, and the regulatory framework.